Macrolide resistance among invasive Streptococcus pneumoniae isolates - PubMed (original) (raw)
. 2001 Oct 17;286(15):1857-62.
doi: 10.1001/jama.286.15.1857.
K Gay, D S Stephens, D J Vugia, M Pass, S Johnson, N L Barrett, W Schaffner, P R Cieslak, P S Maupin, E R Zell, J H Jorgensen, R R Facklam, C G Whitney; Active Bacterial Core Surveillance/Emerging Infections Program Network
Affiliations
- PMID: 11597287
- DOI: 10.1001/jama.286.15.1857
Macrolide resistance among invasive Streptococcus pneumoniae isolates
T B Hyde et al. JAMA. 2001.
Abstract
Context: Macrolide antibiotics, including erythromycin, clarithromycin, and azithromycin, are the mainstays of empirical pneumonia therapy. Macrolide resistance among Streptococcus pneumoniae, the most common cause of community-acquired pneumonia, is increasing in the United States. Whether resistance is a significant problem or whether macrolides remain useful for treatment of most resistant strains is unknown.
Objective: To examine the epidemiology of macrolide-resistant pneumococci in the United States.
Design and setting: Analysis of 15 481 invasive isolates from 1995 to 1999 collected by the Centers for Disease Control and Prevention's Active Bacterial Core surveillance system in 8 states.
Main outcome measures: Trends in macrolide use (1993-1999) and resistance and factors associated with resistance, including examination of 2 subtypes, the M phenotype, associated with moderate minimum inhibitory concentrations (MICs), and the MLS(B) phenotype, associated with high MICs and clindamycin resistance.
Results: From 1993 to 1999, macrolide use increased 13%; macrolide use increased 320% among children younger than 5 years. Macrolide resistance increased from 10.6% in 1995 to 20.4% in 1999. M phenotype isolates increased from 7.4% to 16.5% (P<.001), while the proportion with the MLS(B) phenotype was stable (3%-4%). The median erythromycin MIC (MIC(50)) of M phenotype isolates increased from 4 microg/mL to 8 microg/mL. In 1999, M phenotype strains were more often from children than persons 5 years or older (25.2% vs 12.6%; P<.001) and from whites than blacks (19.3% vs 11.2%; P<.001).
Conclusions: In the setting of increasing macrolide use, pneumococcal resistance has become common. Most resistant strains have MICs in the range in which treatment failures have been reported. Further study and surveillance are critical to understanding the clinical implications of our findings.
Similar articles
- Macrolide resistance among middle ear isolates of Streptococcus pneumoniae observed at eight United States pediatric centers: prevalence of M and MLSB phenotypes.
Mason EO Jr, Wald ER, Bradley JS, Barson WJ, Kaplan SL; United States Pediatric Multicenter Pneumococcal Surveillance Study Group. Mason EO Jr, et al. Pediatr Infect Dis J. 2003 Jul;22(7):623-7. doi: 10.1097/01.inf.0000073124.06415.93. Pediatr Infect Dis J. 2003. PMID: 12867838 - Differentiation of resistance phenotypes among erythromycin-resistant Pneumococci.
Montanari MP, Mingoia M, Giovanetti E, Varaldo PE. Montanari MP, et al. J Clin Microbiol. 2001 Apr;39(4):1311-5. doi: 10.1128/JCM.39.4.1311-1315.2001. J Clin Microbiol. 2001. PMID: 11283047 Free PMC article. - High prevalence of multidrug-resistant international clones among macrolide-resistant Streptococcus pneumoniae isolates in immunocompromised patients in Tunisia.
Raddaoui A, Tanfous FB, Chebbi Y, Achour W, Baaboura R, Benhassen A. Raddaoui A, et al. Int J Antimicrob Agents. 2018 Dec;52(6):893-897. doi: 10.1016/j.ijantimicag.2018.04.015. Epub 2018 Apr 24. Int J Antimicrob Agents. 2018. PMID: 29698665 - Macrolide Resistance in Streptococcus pneumoniae.
Schroeder MR, Stephens DS. Schroeder MR, et al. Front Cell Infect Microbiol. 2016 Sep 21;6:98. doi: 10.3389/fcimb.2016.00098. eCollection 2016. Front Cell Infect Microbiol. 2016. PMID: 27709102 Free PMC article. Review. - A review of clinical failures associated with macrolide-resistant Streptococcus pneumoniae.
Rzeszutek M, Wierzbowski A, Hoban DJ, Conly J, Bishai W, Zhanel GG. Rzeszutek M, et al. Int J Antimicrob Agents. 2004 Aug;24(2):95-104. doi: 10.1016/j.ijantimicag.2004.03.008. Int J Antimicrob Agents. 2004. PMID: 15288306 Review.
Cited by
- Antibiotic persistence and its impact on the environment.
Gangar T, Patra S. Gangar T, et al. 3 Biotech. 2023 Dec;13(12):401. doi: 10.1007/s13205-023-03806-6. Epub 2023 Nov 16. 3 Biotech. 2023. PMID: 37982084 Review. - Levofloxacin versus ceftriaxone and azithromycin for treating community-acquired pneumonia: a randomized clinical trial study.
Yadegarynia D, Tehrani S, Nejad Maghsoudi F, Shojaeian F, Keyvanfar A. Yadegarynia D, et al. Iran J Microbiol. 2022 Aug;14(4):458-465. doi: 10.18502/ijm.v14i4.10231. Iran J Microbiol. 2022. PMID: 36721509 Free PMC article. - Fever of Unknown Origin and Multidrug Resistant Organism Colonization in AML Patients.
Guarnera L, Trotta GE, Boldrini V, Cardillo L, Cerroni I, Mezzanotte V, Pasqualone G, Savi A, Borsellino B, Buzzatti E, Palmieri R, Paterno G, Maurillo L, Buccisano F, Venditti A, Del Principe MI. Guarnera L, et al. Mediterr J Hematol Infect Dis. 2023 Jan 1;15(1):e2023013. doi: 10.4084/MJHID.2023.013. eCollection 2023. Mediterr J Hematol Infect Dis. 2023. PMID: 36660358 Free PMC article. - Pattern of acquisition of hospital-associated pathogens in the ICU of an academic tertiary care hospital.
Damji S, Perrott J, Shajari S, Grant J, Wong T, Harbin M. Damji S, et al. J Assoc Med Microbiol Infect Dis Can. 2022 Jun 3;7(2):108-116. doi: 10.3138/jammi-2021-0025. eCollection 2022 Jun. J Assoc Med Microbiol Infect Dis Can. 2022. PMID: 36337356 Free PMC article. - Clinical significance of viral-bacterial codetection among young children with respiratory tract infections: Findings of RSV, influenza, adenoviral infections.
Jung J, Seo E, Yoo RN, Sung H, Lee J. Jung J, et al. Medicine (Baltimore). 2020 Jan;99(2):e18504. doi: 10.1097/MD.0000000000018504. Medicine (Baltimore). 2020. PMID: 31914021 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical